This Teachable Moment explores innovations that improve the ability to treat disease but increase the potential to cause harm, and thus the importance of careful consideration of who should be treated, what with, and for how long.
This study examines the association between age and the risk of bleeding and thrombosis in patients older than70 years who were treated with a vitamin K antagonist.
In a nationally representative sample of older adults, this study characterizes changes in the prevalence of medication use and quantifies the frequency and types of potential major drug-drug interactions.
This cohort study notes an increased risk of bleeding in patients receiving bridge therapy during warfarin interruption for invasive procedures.
This retrospective cohort study reports a higher incidence of major bleeding and a higher risk of gastrointestinal bleeding with dabigatran.
Albrecht et al estimate the risk of thrombotic and hemorrhagic events associated with warfarin therapy resumption following traumatic brain injury.
Stergiopoulos and Brown compare genotype-guided initial dosing of warfarin and its analogues with clinical dosing protocols. See also the Invited Commentary by Kazi and Hlatky.
Clark et al compare the risk of excessive anticoagulation among patients with stable warfarin therapy purchasing an antibiotic with the risk in patients purchasing a warfarin refill and patients with upper respiratory tract infection but not receiving an antibiotic. Katz provides an editorial.